AccuMetab™ Human CYP2J2 Enzyme, Catalytically Active

CAT#: ITS-0426-YL28
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human CYP2J2 for accurate Phase I drug metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
Highly expressed in the human heart, CYP2J2 is a critical enzyme responsible for converting arachidonic acid into cardioprotective epoxyeicosatrienoic acids. ADME researchers rely on this isoform to predict cardiac-specific drug clearance and flag early cardiotoxicity risks during preclinical development.
Key Features
Highly specific cardiac metabolism model; Validated for arachidonic acid conversion; Essential for early-stage cardiotoxicity screening; Supplied in controlled, low-reductase formats
Applications
Drug Metabolism Studies, Reaction Phenotyping, DDI Assessment, Metabolite ID
Research Areas
ADME, Cardiovascular Pharmacology
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry